MarketBeat
22 Sept 2026, 08:02 UTC · 1h ago
Verdict
Headline leans bullish. We score ABEO +0.60 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.60strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish · 0 new · 5 priced in
Physicians and qualified centers have identified over 100 potential ZEVASKYN candidates.
Priced inmanagement remarks at Morgan Stanley conference
So whatAssuming 2 treatments per lifetime as cited, this pipeline represents a ceiling of ~200 total billable events.
More positive than 92% of claims this week
The company has onboarded seven qualified treatment centers, covering approximately 40% of the addressable patient population.
Continue reading
5 related stories
More positive than 71% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced inmanagement remarks at Morgan Stanley conference
So whatExpanding the network to reach the remaining 60% of patients will be the primary driver of revenue growth in FY2026.
More positive than 76% of claims this week
ZEVASKYN has a restrictive 84-hour shelf life requiring precise alignment between manufacturing and surgical teams.
Priced inmanagement remarks at Morgan Stanley conference
More negative than 79% of claims this week
Commercial turnaround times for ZEVASKYN typically range from 23 to 26 days.
Priced inmanagement remarks at Morgan Stanley conference
More positive than 49% of claims this week
More than 95% of commercial insurance lives have coverage for ZEVASKYN.
Priced inmanagement remarks at Morgan Stanley conference
So whatHigh coverage rates minimize the likelihood of payment disputes impacting gross margins during the initial rollout.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
The company is successfully transitioning to commercial stage with first patients treated and high insurance coverage for ZEVASKYN.
More positive than 44% of ticker scores this week
Mentioned as a market incumbent whose product VYJUVEK is being used by patients who then transition to Abeona's therapy for unmet needs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
ABEO hasn't traded since this ran. Last close $5.67 (Sep 21); the reaction starts at the next open.
ABEO chart →